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In the hippocampus, impaired neurophysiology, compromised neurogenesis, and eventually apoptosis accompany cognitive deficits in
insulinopenic (type-1) diabetes (T1D). The underlying pathological mechanisms remain to be defined. The hippocampus has a high density of the
cannabinoid type 1 receptor (CB1R), which has been shown to control several brain functions affected by diabetes, such as synaptic plasticity,
glucose utilisation, memory consolidation and cognition, and maturation and survival of hippocampal neurons. However, the role of this receptor
has not been investigated yet in diabetic encephalopathy. We report now that in the streptozotocin animal model of T1D, the hippocampal
densities of CB1R protein and of specific CB1R binding sites are significantly increased both in the nerve terminals and in total membranes
(changes between 13% and 38%), whereas CB1R mRNA expression is decreased by 25%, suggesting that CB1Rs might play a role in diabetic
encephalopathy.
© 2006 Elsevier Inc. All rights reserved.Diabetes mellitus is the most common metabolic disorder in
man. It affects a plethora of tissues and organs, including the
brain. “Diabetic encephalopathy” encompasses characteristic
biochemical, electrophysiological, morphological and cogni-
tive deficits in diabetic patients (for review see Trudeau et al.,
2004). T1D rats display a similar cognitive impairment and
display compromised long-term potentiation (LTP) and marked
changes in the density of pre- and postsynaptic synaptic
markers, decreased cell proliferation, and apoptosis have all
been observed in certain cortical regions (Chabot et al., 1997;
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doi:10.1016/j.expneurol.2006.11.0132002). However, the etiology of diabetic encephalopathy is
still ill-defined.
CB1Rs are ubiquitously expressed in the brain, where they
are mostly located presynaptically (although also located
postsynaptically) in a wide range of neurons (for review see
Mackie, 2005). In particular, they are highly abundant in the
human and the rodent hippocampus (Katona et al., 1999, 2000;
Degroot et al., 2006; for review see Mackie, 2005). Activation
of presynaptic hippocampal CB1Rs diminishes the release of
GABA (Katona et al., 1999, 2000), glutamate (Kawamura et al.,
2006), dopamine and acetylcholine (Degroot et al., 2006).
These neurochemical findings may underlie the ability of CB1R
activation to control cognition and memory consolidation
(Hampson and Deadwyler, 1999). Apart from their role in
controlling neurotransmitter release, CB1Rs also control ion
channels and intracellular signaling pathways that are linked to
apoptotic processes (for review see Guzmán et al., 2001). CB1R
activation also can promote adult hippocampal neurogenesis
(Jiang et al., 2005), and regulate subtype-selective interneuron
480 Brief Communicationmigration and specification (Berghuis et al., 2005). Of
particular interest is the finding that in several brain areas
including the hippocampus, CB1R has been shown to modulate
glucose utilisation (Pontieri et al., 1999; Freedland et al., 2003).
In other words, CB1Rs are intricately involved in a wide
spectrum of physiological and pathological mechanisms that
are affected in diabetic encephalopathy. Thus, we aimed to test
whether the density and the expression of CB1Rs receptor is
changed in a classic animal model of T1D.
Animals were handled according with the EU guidelines for
use of experimental animals (86/609/EEC). Diabetes was
induced in 8-week-old male Wistar rats (Harlan Ibérica,
Barcelona, Spain) with i.p. injection of streptozotocin (STZ,
65 mg/kg), dissolved in citrate buffer (10 mM, pH 4.5). Blood
glucose levels were measured with a glucometer (Elite, Bayer-
Portugal). Age-matched, vehicle-injected control rats were
maintained in the same conditions, i.e. with food and water ad
libitum. 30 days after the STZ treatment, rats were decapitated
under halothane anaesthesia. Both hippocampi were rapidly
dissected on ice and total membranes from the hippocampus
were prepared as previously described (Köfalvi et al., 2005;
Duarte et al., 2006). Briefly, the hippocampal tissue from each
rat was homogenized at 4 °C in sucrose solution (0.32 M,
containing 10 mM HEPES, 1 mM EDTA and 1 mg/ml BSA,
pH 7.4), then centrifuged at 3000×g for 10 min at 4 °C. The
supernatant was centrifuged at 14,000×g for 20 min at 4 °C, and
an aliquot was resuspended in 5% (w/v) sodium dodecyl
sulphate (SDS) solution. To obtain nerve terminal-enriched
(synaptosomal) membranes, the remainder of the supernatant
was resuspended in 1 ml of a 45% (v/v) Percoll solution made up
in a Krebs solution (in mM: NaCl 140, KCl 5, HEPES 10, EDTA
1, glucose 1, pH 7.4). After centrifugation at 14,000×g (for 2min
at 4 °C), the top layer was washed in 1 ml Krebs solution and
resuspended in 5% (w/v) SDS solution. Western blotting was
performed as previously described (Köfalvi et al., 2005; Duarte
et al., 2006). Briefly, protein concentration was determined and
each sample was diluted with 5 volumes of SDS–PAGE buffer
containing 30% (v/v) glycerol, 0.6 M dithiothreitol, 10% (w/v)
SDS and 375 mM Tris–HCl, pH 6.8, boiled at 95 °C for 5 min
and incubated for 2 h at 37 °C. Three different dilutions of the
samples and pre-stained molecular weight markers (Amersham,
UK) were loaded into polyacrylamide gels (7.5%), separated
according to protein molecular weight by SDS–PAGE under
reducing conditions, and then electro-transferred to polyvinyli-
dene difluoride membranes (0.45 μm, Amersham). After
blocking for 2 h at room temperature with 5% milk in Tris-
buffered saline (pH 7.6; containing 0.1% Tween 20 (TBS-T)),
membranes were incubated overnight at 4 °C with the L-15
rabbit anti-CB1R antibody, directed against the last 15 amino
acids of the rat CB1R (1:500 dilution). The selectivity of the
antibody has been confirmed in total membrane preparations,
prepared from the brain of CB1R null-mutant mice (Ledent et al.,
1999) and of CD-1 wild-type mice (Fig. 1). After washing,
membranes were incubated with alkaline phosphatase-conju-
gated anti-rabbit secondary antibody (Amersham, 1:10,000).We
also confirmed that the secondary antibody did not yield any
signal in the absence of the primary antibody. After three 20-minwashes in TBS-T with 0.5% milk, membranes were incubated
with Enhanced Chemi-Fluorescence reagent (Amersham) for
5 min and then digitalized with a VersaDoc 3000 (Bio-Rad,
USA), and densitometrically analyzed using the Quantity One
(Bio-Rad) software package. Membranes were then stripped and
re-probed with an anti-α-tubulin antibody (1:3000; Zymed
Laboratories) to confirm that equal amounts of protein were
applied to the gels. Radioligand binding assays were performed
essentially identically to a previous study (Thomas et al., 1998).
Briefly, hippocampal (either total or nerve terminal-enriched)
membranes were resuspended in the incubation buffer (50 mM
Tris, 2 mM MgCl2, 1 mM EGTA, pH 7.4). A saturation curve
was constructed using 5 different concentrations (0.25–10 nM)
of the CB1R receptor antagonist [
3H]SR141716A (Amersham,
42.0 Ci/mmol). Binding was carried out for 1 h at room
temperature (23–25 °C) with 32–51 μg of protein in a final
volume of 200 μl of the incubation buffer. Specific binding was
determined by subtraction of the non-specific binding, which
was measured in the presence of 10 μM AM251 (Tocris),
another selective CB1R antagonist. All binding assays were
performed in duplicate. The binding reactions were stopped by
rapid vacuum filtration through glass fiber filters (GF/C filters;
Whatman) using a 24-well Brandel harvester, followed by
washing with 5 ml of incubation buffer containing 0.5% (w/v)
BSA. The filters were then placed in scintillation vials with 4 ml
of scintillation liquid (Packard Ultima Gold). The specific
binding derived from these saturation experiments was fitted by
non-linear regression to a one binding site equation, using the
Raphson–Newton method, performed with a commercial
software (GraphPad), to determine the binding parameters
(dissociation constant, KD; and maximal number of binding
sites, Bmax). For quantitative real-time PCR (QRT-PCR)
analysis, we began by extracting total RNA from hippocampal
tissue with MagNA Lyser Instrument and MagNA Pure
Compact RNA Isolation kit (Roche, Portugal), according to
the manufacturer's instructions. Reverse transcription for first-
strand cDNA synthesis from each sample was performed using
random hexamer primer with the Transcriptor First Strand
cDNA Synthesis kit (Roche) according to manufacturer's
instructions. Resulting cDNAs were used as template for real-
time PCR, which was carried out on LightCycler instrument
(Roche) using the FastStart DNA Master SYBR Green I kit
(Roche), and CB1R mRNA expression was calculated relative
to β-actin mRNA expression. The following primers (obtained
from Tib MolBiol, Germany) were used (accession numbers
from NCBI database in parenthesis): CB1R (NM_012784):
forward 5′-AGA CCT CCT CTA CGT GGG CTC G -3′,
reverse 5′-GTA CAG CGATGG CCA GCT GCT G-3′, which
originates a 314-bp product (Hansson et al., 2007); and β-actin
(V01217): forward 5′-AAG TCC CTC ACC CTC CCA AAA
G-3′, reverse 5′-AAG CAA TGC TGT CAC CTT CCC-3′,
originating a 97-bp product (Peinnequin et al., 2004). Quan-
tification was carried out based on standard curves run
simultaneously with the test samples. The CB1R and β-actin
standards were generated by conventional PCR amplification.
The PCR products were run in a 3% agarose gel electrophoresis
to verify fragment size and the absence of other contaminating
Fig. 1. (A) Representative Western blots comparing the CB1R immunoreactivity (∼53 kDa band) in total hippocampal membranes (upper left panel) and nerve
terminal-enriched membranes (upper right panel) from control and STZ-treated rats. In all Western blotting evaluations, we confirmed that identical amounts of protein
were loaded in control and test samples by evaluating α-tubulin immunoreactivity, as shown in the top panels. Middle panel: CB1R immunoreactivity is absent in the
membrane preparation (40 μg protein loaded) of the CB1R knockout mouse but a specific band is present at ∼55 kDa in the membrane preparation from the wildtype
(WT) CD-1 mouse, confirming the selectivity of the antibody. Lower left and right panels: densities of the CB1R at each protein concentration. Each data point
represents the mean±SEM of CB1R immunoreactivity from six different control rats (open symbols) and six STZ-treated rats (filled symbols), at three different protein
loads, ensuring that there is indeed a constant increase of CB1R immunoreactivity in hippocampal membrane preparations of rats, 30 days after STZ treatment.
⁎P<0.05 control vs. treated. (B) Maximal specific binding (Bmax) of the selective CB1R antagonist [
3H]SR141716A in rats 30 days after vehicle or STZ injection. Non-
specific binding was determined in the presence of another selective CB1R antagonist, AM251 (10 μM). Bars represent mean±SEM from four different rats, run in
duplicate; ⁎P<0.05. (C) Expression of CB1R mRNA in rats 30 days after vehicle or STZ injection. CB1R mRNA levels (copies/μl) were determined with QRT-PCR
and normalized to the level of β-actin mRNA. Bars represent mean±SEM from seven different rats, run in triplicate; ⁎P<0.05.
481Brief Communicationfragments, quantified by 260 nm absorbance, and serially
diluted to produce the standard curve (100 to 108 copies/μl).
Each real-time PCR reaction was run in triplicate and contained
2 μl of cDNA template, 0.3 μMof each primer, and 3 or 3.5 mM
MgCl2 (for CB1R or β-actin, respectively), in a reaction volume
of 20 μl. Cycling parameters were (for CB1R or β-actin,
respectively): 95 °C for 10 min to activate DNA polymerase,
followed by 40 or 45 cycles at 95 °C for 10 s, annealing
temperature of 62 °C for 10 s or 61 °C for 5 s, and a final
extension step at 72 °C for 14 s or 4 s, in which fluorescence
was acquired. Melting curve analysis was performed to ensurethat only a single product was amplified. Data are presented as
mean±SEM (or as mean and 95% confidence interval for KD
values). Student's t-test was used to compare data and
significance was considered to be reached when P<0.05.
STZ destroys pancreatic β-cells hampering insulin release
(Gai et al., 2004; Szkudelski, 2001), a key feature of T1D.
Accordingly, blood analysis showed that STZ-treated rats
developed sustained hyperglycemia at days 3 and 30 (Table 1)
following STZ treatment. Furthermore, STZ-treated rats failed to
gain body weight (Table 1). As illustrated in Fig. 1A, STZ-
treatment significantly increased CB1R immunoreactivity in
Table 1
Body weight and glycemia of the rats used in the experiments before and after
the induction of diabetes (n=6 for each condition)
Weight (g) Glycemia (mg/dl)
Control STZ-treated Control STZ-treated
Before treatment 225±14 231±11 91±4 96±6
3 days after treatment n.d. 221±7 n.d. 460±14⁎
1 month after treatment 327±21⁎ 208±15⁎⁎ 93±1 448±24⁎,⁎⁎
n.d.: not determined.
⁎ P<0.01, different from before treatment.
⁎⁎ P<0.01, different from control.
482 Brief Communicationtotal membranes (13.0±2.5%, n=6, P<0.05), as well as in
nerve terminal-enriched membranes (14.8 ± 3.7%, n=6,
P<0.05), derived from the hippocampus. These data correspond
to the average of the mean differences found for each tested
amount of protein. Previously, we observed that changes in
protein density in membranes may not automatically mean
similar changes in the density of binding sites (Duarte et al.,
2006). Thus, we analysed CB1R binding in total and nerve
terminal-enriched membranes. We found a 38% increase in the
Bmax (a measure of the density of the receptor) in the total
membranes of the hippocampus of the STZ-treated rats (n=4,
P<0.05, Fig. 1B), and an 18% increase in the nerve terminal-
enriched membranes (n=4, P<0.05, Fig. 1B). These different
percentage (i.e. relative) increases of CB1R density might
correspond to similar absolute amounts of CB1Rs since the Bmax
of [3H]SR141716A was 86% greater (P<0.05) in nerve
terminal-enriched than in total hippocampal membranes (Fig.
1B, black bars). In parallel, we observed that the KD values (a
measure of the affinity of a ligand for a receptor) tend to increase
upon STZ treatment, although this did not reach the level of
significance (from 1.61 nM [95% confidence interval: 1.21–
2.01 nM] to 2.71 nM [1.80–3.62 nM] in total membranes; and
from 1.06 nM [0.89–1.24 nM] to 1.59 nM [1.10–2.08 nM] in
nerve terminal-enriched membranes). To test if increased CB1R
density in hippocampal membranes of STZ-treated rats is due to
an altered mRNA expression, we performed QRT-PCR in total
hippocampal membranes obtained from vehicle-injected and
STZ-treated rats, 30 days after injection. Melting curve analysis
confirmed that one single product has been obtained. Intrigu-
ingly, the expression of CB1R mRNA (normalized to β-actin
from the same sample) is significantly decreased by 25% (n=7,
P<0.05, Fig. 1C) in the STZ-treated animals.
Involvement of the CB1R in metabolic disorders such as
obesity and non-insulin-dependent diabetes (T2D) has attracted
much attention in the last decade. Deletion of CB1Rs leads to
leanness and resistance to diet-induced obesity (Cota et al.,
2003), which anticipates a major role for CB1Rs in controlling
T2D, given that obesity is a major risk factor for T2D. CB1Rs
can also control insulin levels (Juan-Pico et al., 2006, Matias et
al., 2006), and CB1R blockade can decrease hyperinsulinemia in
obese subjects (Gelfand and Cannon, 2006). Furthermore, obese
and/or hyperglycemic T2D patients exhibit higher endocanna-
binoid concentrations in serum and visceral fat (Matias et al.,
2006). Accordingly, therapy with the CB1R antagonist
SR141716A (introduced to the European market under thename of Acomplia) is associated with weight loss, favourable
changes in serum lipid levels, improved glycemic control in pre-
diabetic and T2D patients, and decreased hyperinsulinemia in
obese subjects (Gelfand and Cannon, 2006; Matias et al., 2006).
However, to date, no report has suggested that CB1Rsmight play
a role in T1D. In our T1D model, using STZ, we show now for
the first time that CB1R density is increased both in the total and
in the nerve terminal-enriched membrane fraction in the rat
hippocampus. This increased density of presynaptic CB1Rs may
reflect an elevated neuromodulator power for the CB1R. In the
hippocampus, endogenous activators of the CB1R (i.e. endo-
cannabinoids such as anandamide or 2-arachidonoyl glycerol)
are released upon postsynaptic activation and then travel back to
the presynaptic site to activate presynaptic CB1Rs, inhibiting
transmitter release (for review see Freund et al., 2003). This so-
called retrograde transmission participates in both short and long
forms of synaptic plasticity thought to be key elements of
cognitive behaviour. LTP is impaired in STZ-induced diabetic
animals (for review see Trudeau et al., 2004), which also display
an impairment of Ca2+-dependent regulation of postsynaptic
AMPA receptors (Chabot et al., 1997). Since endocannabinoids
can facilitate the induction of LTP in the hippocampus via
presynaptic blockade of GABAergic neurotransmission (Carl-
son et al., 2002) the upregulation of presynaptic CB1Rs may
contribute to restoring normal LTP functions. Alternatively, the
increased CB1Rs density may be an adaptive response to
counterbalance impaired postsynaptic Ca2+ level regulation and
AMPA functions that result in a diminished endocannabinoid
release. Opposing to these, CB1R activation can restrict LTP via
presynaptic CB1R activation in glutamatergic terminals (Slanina
et al., 2005). Clearly, further functional studies will be required
to explore the modification of CB1R signalling in GABAergic
and glutamatergic synapses in the hippocampus of STZ-treated
rats to pinpoint the exact functional relevance of this modified
density of CB1Rs. It is of interest to note that we previously
found that other G protein-coupled receptors (adenosine
receptors) also undergo changes in their density after STZ
treatment (Duarte et al., 2006). However, as for CB1Rs, only
functional studies will allow establishing if these changes in
adenosine receptors are compensatory or part of the pathophy-
siological mechanisms in T1D. The observed increase in CB1R
density in total membranes upon STZ treatment suggests that
there is a broader modification of CB1R function in T1D. In fact,
total membranes include a minority of synaptic component
(<3%) and a majority of non-synaptic as well as intracellular
membranes. Elevated CB1R density in these fractions may
reflect a compensatory role for CB1Rs not only in synaptic
plasticity but also in metabolic control, cell survival and
neurogenesis. Indeed, CB1Rs, forming heterodimers with
TrkB NGF receptors, are responsible for correct migration and
axonal arborization of certain neurons (Berghuis et al., 2005).
The level of phosphorylated (active) Akt is also increased in the
STZ model of diabetes, with a concomitant increase in levels of
phosphorylated (inactive) glycogen synthase kinase 3β
(GSK3β) (Clodfelder-Miller et al., 2005). Since CB1Rs can
activate the survival factor Akt (Gómez del Pulgar et al., 2002),
and thus indirectly inhibit GSK3β, they can promote survival, as
483Brief Communicationwell as dendritic arborization, which are normally controlled by
the active form of GSK3β (for review see Kalkman, 2006).
Controlling glucose utilisation of hippocampal neurons (Pontieri
et al., 1999; Freedland et al., 2003) is another aspect whereby
CB1Rs may either worsen or improve neuronal functions and
survival chances in the absence of insulin, i.e. in T1D. Finally,
the hypothesis that CB1Rs might control glia-related functions,
such as neuroinflammation, should not be excluded given that
total membranes also include glial membranes. One striking
aspect of our study was the observed disparity between changes
in the expression and the density of CB1Rs after STZ treatment.
This suggests either a modification of protein translation, as was
reported to occur in the hippocampus after traumatic brain injury
(Chen et al., in press), where activation of a key rate-limiting
translational pathway (the mTOR pathway) is observed; or
alternatively a modification of the half-life of CB1Rs that might
be related to oxidative stress found in the hippocampus of STZ-
injected rats (Ates et al., 2006).
In conclusion, the elevated density of the CB1R protein and
CB1R binding sites may represent a compensatory or a
pathophysiological process. This change can either counteract
or contribute to pathophysiological, structural and eventually,
cognitive abnormalities, which involve synaptic deficits,
hampered cell proliferation and apoptosis upon sustained
hyperglycemia. Therefore, this study prompts the need to
explore if the CB1R antagonist SR141716A, which is now a
therapeutically used drug, would worsen or improve neuro-
pathological consequences of T1D.
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